At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Siltuximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease
In Brief
A Phase 2 clinical trial evaluating Siltuximab for Multicentric Castleman's Disease. Completed, enrolled 60 participants across 26 sites in 17 countries.
Detailed Summary
The purpose of this study is to evaluate the long-term safety of siltuximab in patients with multicentric Castleman's disease (MCD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMulticentric Castleman's Disease
CountriesBelgium, Brazil, Canada, China, Egypt, France, Germany, Hong Kong, Israel, New Zealand, Norway, Singapore, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2011
First PostedJul 2011
Primary CompletionMar 2017
TodayJul 2026
First PostedJul 22, 2011
Enrollment StartApr 1, 2011
Primary CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 14.9 years ago
Interventions
Siltuximabdrug
Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.